This synergy is currently under investigation in prospective clinical trials, especially to evaluate abscopal responses following RT in patients with metastatic melanoma treated with ipilimumab (therapy with CTLA-4 blockade) [44,45]. Here, CTLA4 is linked to metastatic melanoma.